

**AACR Virtual Meeting
Myeloma - Discovery to Therapy**

April 26-27, 2021

Conference Cochairs

Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA

Irene M. Ghobrial, Dana-Farber Cancer Institute, Boston, MA

Day 1: April 26, 2021

10:00-11:20 a.m.

**Session 1: Disease Progression from Precursor
Conditions to Myeloma**

10:00-10:05 a.m.

Introduction

10:05-10:20 a.m.

**The genomic basis of smoldering multiple myeloma
progression**

Salomon Manier, University of Lille, Lille, France

10:20-10:35 a.m.

**Imaging-based predictors of disease progression in early
stages of monoclonal plasma cell disorders**

Jens Hillengass, Roswell Park Comprehensive Cancer
Center, Buffalo, NY

10:35-10:50 a.m.

When to treat smoldering myeloma patients?

María-Victoria Mateos, University of Salamanca, Salamanca,
Spain

10:50-11:20 a.m.

Panel Discussion

*Moderators: Irene Ghobrial, Dana-Farber Cancer Institute, Boston, MA, and Ola Landgren,
University of Miami Sylvester Comprehensive Cancer Center, Miami, FL*

Panelists: Salomon Manier, Jens Hillengass, María-Victoria Mateos

11:20-11:35 a.m.

Break

11:35 a.m.-12:55 p.m.

Session 2: Genomics and Epigenetics of Myeloma

11:35 -11:40 a.m.

Introduction

11:40-11:55 a.m.

**Understanding multiple myeloma life history using
whole-genome sequencing**

Francesco Maura, University of Miami Sylvester
Comprehensive Cancer Center, Miami, FL

11:55 a.m.-12:10 p.m.

**Biological and therapeutic insights through CRISPR-
based studies in myeloma**

Constantine Mitsiades, Dana-Farber Cancer Institute, Boston,
MA

12:10-12:25 p.m. **The definition of high-risk myeloma**
Faith E. Davies, NYU Langone Health, New York, NY

12:25-12:55 p.m. Panel Discussion

*Moderator: **Brian Walker**, Professor at Indiana University–Purdue University Indianapolis, Indianapolis, IN*

Panelists: Faith E. Davies, Francesco Maura, Constantine Mitsiades

Day 2: April 27, 2021

10:00-11:20 a.m. **Session 3: Myeloma Microenvironment and Immunotherapy**

10:00-10:05 a.m. Introduction

10:05-10:20 a.m. **Emerging insights into immune microenvironment in myeloma**
Madhav V. Dhodapkar, Emory University, Atlanta, GA

10:20-10:35 a.m. **Future advances in adoptive cellular therapy for MM**
Eric L. Smith, Dana-Farber Cancer Institute, Boston, MA

10:35-10:50 a.m. **Updates in BiTcs and CART: How do we choose the right patient?**
Deepu Madduri, Icahn School of Medicine at Mount Sinai, New York, NY

10:50-11:20 a.m. Panel Discussion

Moderators: Gad Getz, Broad Institute of MIT and Harvard, Cambridge, MA and Nikhil Munshi, Dana-Farber Cancer Institute, Boston, MA

Panelists: Madhav V. Dhodapkar, Eric L. Smith

11:20-11:35 a.m. Break

11:35 a.m.-12:55 p.m. **Session 4: Novel Therapeutics and Drug Resistance**

11:35 -11:40 a.m. Introduction

11:40-11:55 a.m. **Targeting the BCL2 family in multiple myeloma**
Lawrence H. Boise, Emory Winship Cancer Institute, Atlanta, GA

11:55 a.m.-12:10 p.m. **Targeted therapies in relapsed/refractory MM**
Marc S. Raab, Heidelberg University Hospital, Heidelberg, Germany

12:10-12:25 p.m.

Novel therapeutics and drug resistance treatment of lenalidomide refractory patients

Francesca Gay, University of Torino, Torino, Italy

12:25-12:55 p.m.

Panel Discussion

Moderators: Paola Neri, University of Calgary, Calgary, AB, Canada and Paula Rodríguez-Otero, University of Navarra, Pamplona, Spain

Panelists: Lawrence H. Boise, Francesca Gay, Paola Neri

12:55-1:10 p.m.

Break

1:10-2:00 p.m.

Panel Discussion

Bench to Bedside – Application of Lessons Learned from COVID-19 to Clinical Trials and Drug Development in Myeloma

Moderator: Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA

Kenneth C. Anderson

Richard McDonald

Daniel Auclair, Multiple Myeloma Research Foundation, Norwalk, CT

Nicole J. Gormley, FDA Center for Drug Evaluation & Research, Silver Spring, MD

Craig L. Tandler, Johnson & Johnson Pharmaceutical R&D, New Brunswick, NJ